A recombinant human type XVII collagen consists of an amino acid sequence shown in (A).sub.n or includes the amino acid sequence shown in (A).sub.n, where A is a sequence set forth in SEQ ID NO: 2, a sequence undergoing an amino acid modification to a predetermined extent based on SEQ ID NO: 2, or a sequence that has more than 80% homology with SEQ ID NO: 2; n is an integer greater than or equal to 1; and A represents a basic unit, and when there are two or more basic units, the two or more basic units are identical or different and are directly connected in tandem through a peptide bond. In the present disclosure, it is confirmed that the recombinant human type XVII collagen can undergo efficient secretory and soluble expression in eukaryotic host cells such as Pichia pastoris (P. pastoris).

A recombinant human type XVII collagen consists of an amino acid sequence shown in (A).sub.n or includes the amino acid sequence shown in (A).sub.n, where A is a sequence set forth in SEQ ID NO: 2, a sequence undergoing an amino acid modification to a predetermined extent based on SEQ ID NO: 2, or a sequence that has more than 80% homology with SEQ ID NO: 2; n is an integer greater than or equal to 1; and A represents a basic unit, and when there are two or more basic units, the two or more basic units are identical or different and are directly connected in tandem through a peptide bond. In the present disclosure, it is confirmed that the recombinant human type XVII collagen can undergo efficient secretory and soluble expression in eukaryotic host cells such as Pichia pastoris (P. pastoris).

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The invention relates to novel methods for making transparent and curved stromal cell tissues and decellularized forms thereof. Novel tissues are also provided.

The invention relates to novel methods for making transparent and curved stromal cell tissues and decellularized forms thereof. Novel tissues are also provided.

The present invention relates to a “one-pot” method for preparing an aqueous solution of nanoparticles with amphiphilic block copolymers and comprising polypeptide units, the method comprising at least one step (E1), in an aqueous solvent, consisting of bringing together: —at least one hydrophilic polymer (P1) comprising at least one amine function, and —at least one hydrophobic α-amino acid N-carboxyanhydride monomer.

An immune checkpoint inhibitor containing a substance that inhibits binding between fibronectin and an immunosuppressive receptor LILRB4 as an active ingredient, a therapeutic agent for an immune checkpoint-related disease, an immunosuppressant containing a substance that activates an immunosuppressive receptor LILRB4 as an active ingredient, an anti-fibronectin antibody or a derivative thereof, a fibronectin analog, a kit for detecting fibronectin or a partial protein thereof, and a method for detecting fibronectin or a partial protein thereof in a biological sample using the kit.

An immune checkpoint inhibitor containing a substance that inhibits binding between fibronectin and an immunosuppressive receptor LILRB4 as an active ingredient, a therapeutic agent for an immune checkpoint-related disease, an immunosuppressant containing a substance that activates an immunosuppressive receptor LILRB4 as an active ingredient, an anti-fibronectin antibody or a derivative thereof, a fibronectin analog, a kit for detecting fibronectin or a partial protein thereof, and a method for detecting fibronectin or a partial protein thereof in a biological sample using the kit.

The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.